In November 2020, the Shenyang area of China (Liaoning) Pilot Free Trade Zone announced that Qifu Biotech (jointly operating Liaoning Cord Blood Bank with Shengjing Hospital)'s product "Umbilical Cord Blood Hematopoietic Stem Cells" was selected as the "2020 Liaoning Province Small and Medium-sized Enterprise Specialty" List of Special New Products"! It is believed that in the near future, Qifu Bio will gradually become the backbone of innovative technology enterprises in the province, using life technology to create a broader healthy blue ocean.
Liaoning Qifu Stem Cell Biotechnology Co., Ltd. is a high-tech enterprise with stem cell resource storage and stem cell drug diagnosis and treatment as its main business. The company has a research and development center with 18 authorized patents and 8 software copyrights. In terms of stem cell preparation, cryopreservation, resuscitation, amplification, genetic testing, and clinical application, there are profound professional technical precipitation. In February 2019, Qifu Biotechnology passed the ISO9001 quality assurance system certification.
Science is an important internal driving force for development. Qifu Biosciences continues to carry out research and development and transformation of technological achievements in the "High-tech Fields Supported by the State", forming the core independent intellectual property rights of the enterprise, and obtaining high-tech enterprise certification.
The Liaoning Province Cord Blood Bank jointly operated by Qifu Biotech and Shengjing Hospital Affiliated to China Medical University was established with the approval of the Ministry of Health (Weiyifa [2002] No. 62) and was established under the supervision of the Liaoning Provincial Health and Family Planning Commission (Liaoning Banfa [2015] No. 184). In 2017, it moved to the Shenbei campus of Shengjing Hospital Affiliated to China Medical University, with a building area of 8,700 square meters. The storage volume, processing capacity, cleanliness level, information communication, security, and indoor environment control have all reached the standard level.
Liaoning Province Cord Blood Bank is a blood bank set up in Northeast China strictly approved by the former Ministry of Health. It is a blood bank strictly under the direct supervision of the Provincial Health and Family Planning Commission. It is also a qualified public institution in the province that accepts cord blood donations (provincial There are no other qualified public institutions that can accept cord blood donations), and all the testing, preparation, and preservation procedures are all performed by the blood transfusion physician of Shengjing Hospital. Ensure the safe and reliable storage environment of cord blood, and ensure that depositors can take it without worry at any time. The
cord blood bank has established cord blood collection networks in more than 110 hospitals above the second level in 14 cities in the province. To provide better services to newborn cord blood depositors in the province, to provide a more worry-free medical experience for self-storage families, and to provide a more complete medical security system for the whole society is the goal of Qifu Bio and the Liaoning Cord Blood Bank.
Qifu Biotech is selected into the "2020 Liaoning Province Small and Medium-sized Enterprise Specialized and Special New Products List" product-cord blood hematopoietic stem cells, which are the blood remaining between the umbilical cord and the placenta after the fetus is delivered. The original hematopoietic stem cells can rebuild the human blood system and immune system through transplantation. According to the relevant regulations of my country's Health Commission, cord blood stem cell transplantation can be mature and widely used in the treatment of blood system diseases, malignant tumors, some genetic diseases, congenital and metabolic diseases.
Newborn umbilical cord blood contains a large number of primitive hematopoietic stem cells, immune cells, endogenous progenitor cells, natural killer cells, dendritic cells, killer/regulatory T cells, etc. These stem cells have not undergone any external pollution, which is very Valuable medical resources.
started with the first umbilical cord blood transplant operation in 1988, treating a 5-year-old boy with Fancon’s anemia. So far, there have been more than 40,000 successful umbilical cord blood transplants worldwide. With the continuous development of medical technology, there are more than 80 kinds of diseases that can be treated by cord blood, and more than 400 related clinical studies.
cord blood storage is also of great significance to the family, and it is the "protective umbrella" to protect the health of the family. The umbilical cord blood stored by the baby is his own hematopoietic stem cell, which is 100% consistent with itself, that is, it is completely matched, and will not cause rejection after transplantation. In addition, umbilical cord blood can also be used by close relatives at home. It is 100% semi-matched with parents, and the matching success rate between siblings is 25%-50%. According to a study reported by the American Society of Hematology in 2007, the clinical transplantation of related cord blood is better, with a high patient survival rate, and a low incidence of rejection after transplantation, with a mild degree.
Newborn umbilical cord blood is a gift the baby brings to the family, please cherish it! You are welcome to store your cord blood in the Liaoning Province Cord Blood Bank, and hope you will give your trust to Qifu Bio!
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-